Interpace Biosciences, Inc. (IDXG)
OTCMKTS
· Delayed Price · Currency is USD
1.280
+0.210 (19.63%)
Apr 10, 2025, 3:34 PM EDT
Interpace Biosciences Revenue
In the year 2024, Interpace Biosciences had annual revenue of $46.93M with 17.21% growth. Interpace Biosciences had revenue of $12.32M in the quarter ending December 31, 2024, with 21.88% growth.
Revenue
46.93M
Revenue Growth
+17.21%
P/S Ratio
0.12
Revenue / Employee
422.76K
Employees
108
Market Cap
5.66M
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 46.93M | 6.89M | 17.21% |
Dec 31, 2023 | 40.04M | 8.20M | 25.75% |
Dec 31, 2022 | 31.84M | -1.28M | -3.86% |
Dec 31, 2021 | 33.12M | 719.00K | 2.22% |
Dec 31, 2020 | 32.40M | 8.18M | 33.77% |
Dec 31, 2019 | Pro | Pro | Pro |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
SS Innovations International | 16.04M |
Endo Inc. | 1.76B |
Veradigm | 588.02M |
Elite Pharmaceuticals | 70.00M |
Glass House Brands | 200.90M |
Northwest Biotherapeutics | 1.38M |
Global Cord Blood | 196.10M |
American Oncology Network | 1.76B |
Interpace Biosciences News
- 2 months ago - Interpace Biosciences Announces Preliminary Full-year and Fourth Quarter 2024 Financial and Business Results - GlobeNewsWire
- 2 months ago - PancraGEN® Will Continue to be Offered While Interpace Re-evaluates its Previously Announced Re-structuring Plan - GlobeNewsWire
- 3 months ago - Effective 02/07/2025, Interpace Diagnostics® to No Longer Offer PancraGEN®, a Molecular Diagnostic Test That Assesses Pancreatic Cyst Cancer Risk - GlobeNewsWire
- 5 months ago - Interpace Biosciences Announces Record Third Quarter 2024 Financial and Business Results - GlobeNewsWire
- 6 months ago - Interpace Biosciences Announces Capital Restructuring of Its Preferred Stock as a First Step Toward Seeking an Uplisting of Its Common Stock to Nasdaq - GlobeNewsWire
- 9 months ago - Interpace Biosciences Announces Record Second Quarter 2024 Financial and Business Results - GlobeNewsWire
- 9 months ago - Interpace Diagnostics® Announces Undefined Extension of Medicare Coverage for PancraGEN®, a Molecular Diagnostic Test That Assesses Cancer Risk of Pancreatic Cysts - GlobeNewsWire
- 1 year ago - Interpace Biosciences Announces First Quarter 2024 Financial and Business Results - GlobeNewsWire